Key result
DAN-DAPT evaluates genotype-guided de-escalation to reduce bleeding without increasing ischemic risk.
Why the study?
The optimal dual antiplatelet therapy strategy for patients with myocardial infarction and high bleeding risk remains debated, and it is unknown whether genotype-guided DAPT de-escalation and abbreviation is noninferior and reduces bleeding compared with standard DAPT.
Does genotype-guided DAPT de-escalation, with or without abbreviation to 3 months, reduce adverse clinical events and bleeding compared to standard 6-month DAPT in high bleeding risk patients with myocardial infarction undergoing PCI?
RCT (n=2,700)
Open-label (PROBE design for endpoint adjudication)
1:1:1 block randomization stratified by STEMI or non-STEMI
Yes
Does genotype-guided DAPT de-escalation, with or without abbreviation to 3 months, reduce adverse clinical events and bleeding compared to standard 6-month DAPT in high bleeding risk patients with myocardial infarction undergoing PCI?
The ongoing DAN-DAPT trial will provide randomized data on whether genotype-guided de-escalation and/or abbreviation of DAPT to 3 months can safely reduce bleeding without increasing ischemic events in high-bleeding-risk patients after myocardial infarction.
Answers are grounded in this paper and cite their sources.
Results from DAN-DAPT are needed to guide personalized post-PCI DAPT; leaves open optimal de-escalation strategies in genotype-selected patients.
RATIONALE: inhibitor and duration of DAPT. The optimal DAPT strategy for these patients remains debated, and it is unknown whether genotype-guided DAPT de-escalation to clopidogrel and aspirin, with or without abbreviation of DAPT to 3 months, is noninferior in terms of net adverse clinical events (NACE) and superior in reducing bleeding side-effects compared with standard DAPT for 6 months. DESIGN: The DAN-DAPT trial is an investigator-initiated, open-label, multicenter, multiarm, randomized controlled trial conducted at all Danish hospitals performing PCI. From 2022 to 2029, we planned to randomize 2,700 patients with MI and high bleeding risk in a 1:1:1 ratio to 1 of 3 groups: CYP2C19-genotyping and 6 months DAPT (experimental group 1), CYP2C19-genotyping and 3 months DAPT (experimental group 2), and 6 months DAPT with prasugrel (or ticagrelor) and aspirin (control group). The coprimary outcomes are NACE defined as the composite of all-cause mortality, recurrent MI, definite stent thrombosis, stroke, and BARC type 3-5 bleeding (Bleeding Academic Research Consortium), and major and minor bleedings defined as the composite of BARC type 2-5 bleedings at 1 year. CONCLUSION: DAN-DAPT trial is an open-label, multicenter, randomized controlled trial comparing genotype-guided DAPT de-escalation to clopidogrel - with or without DAPT abbreviation to 3 months - and standard DAPT for 6 months after PCI in high bleeding risk patients with MI. As of March 2025, 36% of the planned 2,700 patients have been enrolled in the study. TRIAL REGISTRATION: ClincialTrials.gov (NCT05262803) and EU number (2022-500125-32-00).
No takes yet. Share an insight, caveat, or question.
Jacobsen et al. (2025) conducted an RCT in Myocardial infarction with high bleeding risk (n=2,700). Genotype-guided dual antiplatelet therapy (DAPT) de-escalation with or without 3-month abbreviation vs. Standard DAPT (prasugrel and aspirin) for 6 months was evaluated on Co-primary: Net adverse clinical events (NACE) and BARC type 2-5 nonaccess site bleeding at 1 year. Genotype-guided de-escalation of dual antiplatelet therapy, with or without abbreviation to 3 months, is being evaluated in the ongoing DAN-DAPT trial to reduce bleeding without increasing ischemia.
Synapse has enriched 10 related papers. Consider them for comparative context: